The Top Line Biopharma's rebound keeping pace so far
11 snips
Jan 30, 2026 Kristin Cirello Pothier, KPMG life sciences and global deal strategy leader, discusses the 2026 investment outlook. She reviews 2025 deal lessons, why cost discipline rose after COVID, and which early‑2026 acquisitions signal priorities. Conversations cover FDA uncertainty, manufacturing choices for smaller firms, and how valuations favor proven innovation.
AI Snips
Chapters
Transcript
Episode notes
Proof Over Promise Drives Deals
- KPMG frames 2026 as a year of "proof over promise," with deals backed by deeper diligence and integration planning completed during diligence.
- Companies now insist on clearer value realization before signing deals rather than relying on post-deal fixes.
2025 Fueled Portfolio Cleanup
- 2025 saw lower deal volume but a focus on true innovation and portfolio right-sizing.
- Companies prioritized cost-efficiency moves so they could be prepared for higher-quality deals in 2026.
Right-Size Operations Before Acquiring
- Do prioritize cost discipline and automation before acquiring so you can integrate new assets without bloating costs.
- Trim redundancies and optimize headcount to prepare for future acquisitions.